Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

life.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the data from this study will be fully interpreted or will be submitted to medical meetings in the future. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Rebecca Gregory, Corporate Communications of ImClone SystemsIncorporated, +1-646-638-5058, ; or Media, Madeline Malia,+1-609-252-3347, , or Tony Plohoros, +1-609-252-7938,, or Investors, John Elicker, +1-212-546-3775,, all of Bristol-Myers Squibb media@imclone.com Madeline.Malia@bms.com tony.plohoros@bms.com John.Elicker@bms.com

Web site: http://www.bms.com/http://www.ERBITUX.com/

Ticker Symbol: (NYSE:BMY),(NASDAQ-NMS:IMCL)

Terms and conditions of use apply
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/2/2014)...  VentiRx Pharmaceuticals, Inc., a clinical stage ... commercialization of novel Toll-like receptor 8 (TLR8) ... and clinical activities at the company including ... clinical trials and future clinical development efforts. ... Officer Robert Hershberg , M.D., Ph.D. ...
(Date:9/2/2014)... Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... products marketed as XIAFLEX ® in the U.S. and ... President, Tom Wegman , will present at the following ... Rodman & Renshaw 16 th Annual ... Tuesday, September 9, 2014 at 9:10 a.m. EDT ...
(Date:9/2/2014)... OAKS, Calif. , Sept. 2, 2014 ... today announced the submission of a Marketing ... Agency (EMA) via the centralized procedure for ... of adults with melanoma that is regionally ... oncolytic immunotherapy administered as an intralesional injection ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6
(Date:9/2/2014)... York (PRWEB) September 02, 2014 - ... defined as a class of diagnostic test that analyzes ... The nucleic acids and proteins that belong to individual ... therapy, health condition, or risk of developing a specific ... better known as (MDx) evaluating the new class of ...
(Date:9/2/2014)... A New York City based company ... simple, yet revolutionary, product that will have ... health care costs for Americans. , REMIND-A-CAP™ ... puts control in the user's hands. It's a simple ... next date of intake by simply turning a knob. ...
(Date:9/2/2014)... may help scientists learn why patients with cystic fibrosis ... their lungs are relatively healthy. , The researchers ... treat pulmonary hypertension and Viagra for erectile dysfunction ... help them identify the root of the blood vessel ... , "We want to understand why these patients have ...
(Date:9/2/2014)... there might be a new salve to dominate medicine cabinets ... lowly salamander. Salamanders may not be the cuddliest of animals, ... of seriously damaged body parts. Now, a new report published ... Journal , identifies a small protein (called a "peptide") ... to unlocking the secret of this amazing wound healing trick ...
(Date:9/2/2014)... of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased ... Fellowship. This two-year fellowship, founded in 2008 by the ... Kanji Torizuka, MD, PhD, is designed to provide extensive ... and molecular imaging for Japanese physicians in the early ... proud to sponsor the Wagner-Torizuka Fellowship. This program honors ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2
... moms have lower rates of depression than their stay-at-home counterparts, ... at greater risk for depression, suggests new research to be ... Association. The study shows that working mothers who ... be blended with relative ease showed higher levels of depression ...
... Paper money worldwide is contaminated with the potentially toxic chemical ... is used to make some plastics and consumer products such ... that BPA is an endocrine disruptor, which means that it ... to a number of health problems. Researchers analyzed 156 ...
... Aug. 19 (HealthDay News) -- Some patients do dream while ... still have a form of consciousness about themselves and the ... electroencephalography (EEG) to compare the structure of sleep in 11 ... five in a vegetative state (unresponsive wakefulness). "We used ...
... can reduce the risk of strokes as well as heart ... System neurologists caution that statins may not be appropriate for ... The article, by Dr. Murray Flaster and colleagues, appears in ... Neurotherapeutics . , A landmark 2006 study known as SPARCL, ...
... , THURSDAY, Aug. 18 (HealthDay News) -- A calcium ... to provide insight into the likelihood that certain patients at ... or stroke, researchers say. The test to detect ... take cholesterol-lowering drugs to reduce their cardiovascular risks, the study ...
... For better or for worse, in sickness and in ... associates marriage with reducing unhealthy habits such as smoking, ... However, new research is emerging that suggests married straight ... intimate relationships may pick up each other,s unhealthy habits ...
Cached Medicine News:Health News:Less depression for working moms who expect that they 'can't do it all' 2Health News:Paper Money Worldwide Tainted With BPA: Study 2Health News:People Appear to Dream While in Minimally Conscious State 2Health News:Cholesterial drugs can reduce the risk of stroke, but aren't for everyone 2Health News:Test for Calcium Buildup May Spot Heart Attack, Stroke Risk 2Health News:Long-term, intimate partnerships can promote unhealthy habits 2Health News:Long-term, intimate partnerships can promote unhealthy habits 3
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: